Murine Models Of Dengue And Their Utility For Drug And Vaccine Testing | 48932
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Dengue (DEN), the most serious arthropod-borne viral disease, manifests as a mild febrile illness to life-threatening hemorrhage
and vascular leakage. The development of an animal model has long been recognized as a major roadblock in understanding
dengue pathogenesis and validating therapeutic and prophylactic strategies prior to clinical stages. Humans and mosquitoes are the
natural hosts for dengue virus (DENV) in its urban cycle. While most immunocompetent mice are not susceptible to infection from
all four DENV serotypes, type I & II interferon deficient mice may develop asymptomatic transient viremia and in few cases, relevant
clinical manifestations. Furthermore, it is possible to reproduce the antibody-dependent enhancement of disease severity (ADE)
in this mouse model. In this conference, we will present the various mouse models of dengue currently available in our laboratory,
ranging from asymptomatic transient viremia to lethal models associated with vascular leakage or liver damage, two relevant clinical
manifestations. We will also present our unique models of ADE mediated by maternal antibodies acquired during both gestation and
breastfeeding. This mouse models platform has made our group visible to the Dengue research scene and has attracted a significant
number of collaborations, licensing and research service contracts with both industry partners and public institutions for evaluating
the in vivo efficacy of prophylactic and therapeutic candidates.
Alonso Sylvie has completed her PhD in University Claude Bernard Lyon I, France and pursued her Postdoctoral studies at the Pasteur Institute of Lille, France and Cornell University, NY, USA. She has established laboratory at NUS, Department of Microbiology and Immunology. She is also a Member of the Immunology program at the Life Sciences Institute, NUS. Her main interests lie in host-pathogen interactions with a focus on Dengue, Tuberculosis and Enterovirus 71. She has published more than 60 peer-reviewed papers in reputed journals and has been serving as an Editorial Board Member of PLOS ONE and Frontiers in Immunotherapies and Vaccines.